Literature DB >> 17124603

Protein Z and natural anticoagulants in children on peritoneal dialysis and hemodialysis.

Kenan Bek1, Ozan Ozkaya, Tunç Fişgin, Yüksel Aliyazicioğlu, M Sükrü Paksu, Tolga Ozgen, Davut Albayrak, Kemal Baysal.   

Abstract

Hemostatic alterations due to abnormalities in the coagulation and fibrinolytic system may occur in dialysis patients. Protein Z (PZ) is a vitamin K-dependent coagulation protein promoting assembly of thrombin with phospholipid vesicles. The aim of this study was to investigate PZ and natural anticoagulants in children on hemodialysis (HD) and peritoneal dialysis (PD). Protein Z, protein C (PC), protein S (PS), antithrombin III (AT III), and fibrinogen levels were studied in 24 PD, 13 HD patients and 23 controls. Plasma PZ levels in patients on HD were significantly higher than those on PD and control group (p = 0.04, p = 0.03). We observed elevated PC, PS and AT III activities in children on PD when compared to controls (p = 0.011, p = 0.003, p < 0.001). In HD patients, only PS activity was increased compared to controls (p = 0.016). PC and PS activities did not differ between PD and HD patients whereas AT III activity was higher in PD patients compared to HD patients (p < 0.001). Normal/high levels of PC, PS and AT III suggest that children on PD or HD treatment do not seem to have an increased risk of thrombogenesis due to reduction of these proteins. Increased PZ levels, however, might contribute to the hemostatic alterations in children on HD treatment along with other well known abnormalities.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17124603     DOI: 10.1007/s00467-006-0351-8

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  36 in total

1.  Coagulation cascade, fibrinolytic system, antithrombin III, protein C and protein S in patients maintained on continuous ambulatory peritoneal dialysis.

Authors:  N D Vaziri; G M Shah; R L Winer; E Gonzales; B Patel; S Alikhani; Q X Nguyen; J Yamamoto
Journal:  Thromb Res       Date:  1989-01-15       Impact factor: 3.944

Review 2.  Protein Z.

Authors:  B Kemkes-Matthes; K J Matthes
Journal:  Semin Thromb Hemost       Date:  2001-10       Impact factor: 4.180

3.  Effects of recombinant human erythropoietin on physiological inhibitors of coagulation in children on continuous ambulatory peritoneal dialysis.

Authors:  F A Kisaarslan; Z Gündüz; R Düsünsel; H M Poyrazoglu; R Saraymen; B Elmas
Journal:  Adv Perit Dial       Date:  1999

4.  Protein Z influences the prothrombotic phenotype in Factor V Leiden patients.

Authors:  Bettina Kemkes-Matthes; Margareta Nees; Gitta Kühnel; Axel Matzdorff; Karl J Matthes
Journal:  Thromb Res       Date:  2002-05-15       Impact factor: 3.944

5.  Characterization of the protein Z-dependent protease inhibitor.

Authors:  X Han; R Fiehler; G J Broze
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

Review 6.  Protein Z and vitamin K in kidney disease.

Authors:  J S Małyszko; J Małyszko; E Skrzydlewska; K Pawlak; M Myśliwiec
Journal:  Rocz Akad Med Bialymst       Date:  2004

7.  Frequency of protein Z deficiency in patients with ischaemic stroke.

Authors:  M Vasse; E Guegan-Massardier; J Y Borg; F Woimant; C Soria
Journal:  Lancet       Date:  2001-03-24       Impact factor: 79.321

Review 8.  Hemostasis in renal disease: pathophysiology and management.

Authors:  M E Eberst; L R Berkowitz
Journal:  Am J Med       Date:  1994-02       Impact factor: 4.965

9.  Effects of hemodialysis and long-term erythropoietin treatment on protein C, and on free and total protein S.

Authors:  N Clyne; N Egberg; L E Lins
Journal:  Thromb Res       Date:  1995-10-15       Impact factor: 3.944

10.  A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy.

Authors:  J Malyszko; J S Malyszko; J Borawski; A Rydzewski; M Kalinowski; A Azzadin; M Mysliwiec; W Buczko
Journal:  Thromb Res       Date:  1995-01-15       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.